HC Wainwright Analysts Decrease Earnings Estimates for ATNM

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for Actinium Pharmaceuticals in a research note issued to investors on Monday, August 10th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.27) for the quarter, down from their previous forecast of ($0.24). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at $0.12 EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at ($0.75) EPS.

Actinium Pharmaceuticals Price Performance

Actinium Pharmaceuticals stock opened at $0.79 on Wednesday. The firm’s fifty day moving average price is $0.94 and its 200 day moving average price is $1.09. The company has a market capitalization of $24.88 million, a price-to-earnings ratio of -0.57 and a beta of 0.01. Actinium Pharmaceuticals has a 12-month low of $0.74 and a 12-month high of $1.81.

Institutional Trading of Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new stake in Actinium Pharmaceuticals during the fourth quarter valued at approximately $96,000. Two Sigma Investments LP grew its stake in Actinium Pharmaceuticals by 403.4% during the 3rd quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock worth $375,000 after buying an additional 187,748 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Actinium Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock worth $2,215,000 after acquiring an additional 12,703 shares during the last quarter. Jane Street Group LLC bought a new position in Actinium Pharmaceuticals in the 2nd quarter worth about $306,000. Finally, Marshall Wace LLP acquired a new stake in Actinium Pharmaceuticals in the 2nd quarter valued at approximately $137,000. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.